Fig. 6.

LAPTM4B enhances the effects of EGFR on cell proliferation, migration and invasion and inhibits gefitinib-induced cell apoptosis. a HCC827 cells were transfected with EGFR-specific siRNA with or without LAPTM4B overexpression. Cell viability was determined by CCK-8 assays. Control: transfected scrambled vectors, EGFR-siRNA: transfected with EGFR-specific siRNA, EGFR-siRNA+LAPTM4B:transfected with EGFR-specific siRNA and LAPTM4B overexpression vector. b The effects of EGFR and LAPTM4B on cell migration and invasion were evaluated by transwell assays. c The HCC827 cells were incubated with 0.01 μM gefitinib (Gefitinib group) and DMSO (control group), respectively. After 48 h incubation, cells were harvested and analyzed by FACSCalibur flow cytometer. Each bar represents the mean values±SD of three independent experiments. ***P < 0.001